Abstract 63P
Background
Eribulin, a novel anti-tubulin agent, is a preferred treatment for patients (pts) with metastatic breast cancer (mBC) who have been pretreated with anthracycline and/or taxane-based therapy. Preclinical data suggest a potential synergistic effect of eribulin and platinum. However, clinical data on the combination for mBC are lacking. We evaluated eribulin plus platinum in pts with mBC.
Methods
This multi-center, real-world cohort study included pts with pre-treated metastatic triple- negative breast cancer (TNBC) or endocrine-refractory hormone receptor (HR) -positive, HER2 -negative mBC who received eribulin plus carboplatin (ErCb). Eribulin (1.4 mg/m2) and carboplatin (target AUC=2) were administered intravenously on days 1 and 8 of 21-day cycles. Progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and adverse events (AEs) were evaluated.
Results
From March 2022 to August 2023, 19 pts with TNBC and 11 with HR+HER2- mBC were included. Of the 19 pts with TNBC, 8 had an initial diagnosis of HR+HER2- disease. All 30 pts were female, with a median (range) age of 46 (31–60) years and had received a median of 2 (1–6) prior lines of therapy. Visceral metastases were present in 22 pts (73.3%). Best overall response, ORR, DCR, and PFS are shown in the table. Median overall survival was not reached. After a median of 6 cycles (range, 2–8) of ErCb, the most common grade 3–4 AEs were neutropenia (40.0%), leukopenia (23.3%), febrile neutropenia (10.0%), and anemia (3.3%). No grade 3–4 non-hematological AEs were observed. Table: 63P
Patients, n (%) | |||
Response | All patients (N=30) | TNBC group (N=19) | HR+HER2- group (N=11) |
Complete response | 0 | 0 | 0 |
Partial response | 19 (63.3) | 12 (63.2) | 7 (63.6) |
Stable disease | 7 (23.3) | 4 (21.1) | 3 (27.3) |
Progressive disease | 4 (13.3) | 3 (15.8) | 1 (9.1) |
ORR | 19 (63.3) | 12 (63.2) | 7 (63.6) |
DCR | 26 (86.6) | 16 (84.2) | 10 (91.0) |
Median PFS, months (95% CI) | 5.0 (4.0-6.0) | 5.0 (1.3-8.7) | 5.6 (3.0-8.1) |
Conclusions
In this cohort of pts with heavily pre-treated HER2- mBC, ErCb demonstrated promising efficacy and a manageable safety profile. Further studies exploring this combination in earlier lines of treatment for mBC are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract